Heron Therapeutics | HRTX - Debt


Heron Therapeutics reported $149.65M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 613.76M 3.28M Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
Eisai JPY 186.08B 50.58B Mar/2026
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 725.8M 1.82M Jun/2026
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
Merck USD 49.12B 222M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 363.12M 4.53M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Veracyte USD 39.33M 321K Mar/2026
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026